GO:0001837 epithelial to mesenchymal transition: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001837 (epithelial to mesenchymal transition, EMT) describes the process by which an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components, and becomes a migratory mesenchymal cell.
• EMT is a normal developmental program, prominently deployed during neural crest delamination, and is reactivated in pathological contexts such as carcinoma progression and fibrosis.
• Core molecular hallmarks include loss of E-cadherin, gain of N-cadherin and vimentin, and increased migratory and invasive capacity.
• EMT is transcriptionally controlled by inducers such as SNAI1/SNAI2, TWIST1, ZEB1/ZEB2, and TGFB1 signaling, and is modulated by epigenetic and post-translational regulators including arginine methylation.
• EMT contributes to cancer invasion, metastasis, and therapy resistance across pancreatic, oral, bladder, breast, and bone malignancies.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with CRISPR library screening and bioinformatics, are powerful tools for dissecting EMT gene function.
Description
Epithelial to mesenchymal transition (EMT) is a fundamental biological process in which polarized, adherent epithelial cells convert into motile mesenchymal cells. This transition is defined in the Gene Ontology as GO:0001837 and involves the loss of apical/basolateral polarity, disassembly of intercellular adhesive junctions, degradation of basement membrane components, and acquisition of a migratory mesenchymal phenotype. EMT is essential during embryogenesis, most notably in neural crest delamination, and is aberrantly reactivated in adult tissues during cancer progression and fibrosis. Because EMT sits at the intersection of development, tissue remodeling, and disease, it is a major focus of biomedical research. Understanding its molecular control has direct implications for cancer diagnosis, prognosis, and therapeutic targeting. This article summarizes the definition, mechanism, key genes, disease links, and research methods relevant to GO:0001837, based on published literature.
epithelial to mesenchymal transition At A Glance
| GO ID | GO:0001837 |
|---|---|
| GO term | epithelial to mesenchymal transition |
| Ontology | biological_process |
| Synonym | EMT; epithelial-mesenchymal transition; mesenchymal cell differentiation from epithelial cell |
| Definition | A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. |
| Major function | Conversion of epithelial cells into migratory mesenchymal cells during development and disease |
| Related processes | Neural crest delamination, cancer invasion and metastasis, fibrosis, wound healing |
| Key molecular markers | Loss of E-cadherin; gain of N-cadherin, vimentin, and mesenchymal transcription factors |
What Is GO:0001837?
GO:0001837 (epithelial to mesenchymal transition) is a biological process in which an epithelial cell loses its apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components, and becomes a migratory mesenchymal cell. In other words, it is a coordinated cellular reprogramming event that converts a stationary, tightly connected epithelial cell into a motile, invasive mesenchymal cell.
Why Is epithelial to mesenchymal transition Important in Cell Biology?
EMT is important because it is a central mechanism linking embryonic development to adult pathology. During development, EMT drives neural crest cell delamination and contributes to tissue morphogenesis. In disease, EMT is a hallmark of carcinoma progression, enabling tumor cells to invade, disseminate, and acquire resistance to therapy. It is also implicated in metaplastic breast cancer, phyllodes tumors, osteosarcoma, and bladder cancer, making it a high-value target for mechanistic studies and therapeutic development.
• EMT is essential for neural crest delamination and normal embryonic development.
• EMT promotes cancer cell invasion and metastasis in pancreatic, oral, bladder, and breast cancers.
• EMT is associated with therapy resistance and poor clinical outcomes in multiple malignancies.
• EMT contributes to osteosarcoma progression and metastatic potential.
• EMT is regulated by transcription factors, signaling pathways, and epigenetic modifiers such as arginine methylation.
• EMT markers such as E-cadherin and vimentin are widely used in pathology and research.
• EMT is a model system for studying cell plasticity and differentiation.
• EMT is a target for anti-metastatic and anti-fibrotic therapeutic strategies.
• EMT research benefits from CRISPR-based functional genomics and bioinformatics.
• EMT is conserved across species, enabling comparative developmental studies.
What Happens During epithelial to mesenchymal transition?
Initiation and loss of epithelial polarity
In simple terms: The epithelial cell starts to lose its organized top-bottom structure.
EMT begins with the disruption of apical/basolateral polarity, a defining feature of epithelial cells. This step involves downregulation of epithelial junctional components and polarity complexes, allowing the cell to reorganize its cytoskeleton and prepare for motility. In neural crest cells, this initiation is tightly coupled to delamination from the neuroepithelium.
Disassembly of intercellular adhesive junctions
In simple terms: The cell breaks the glue that holds it to neighboring cells.
A hallmark of EMT is the severing of intercellular adhesive junctions, including adherens junctions and tight junctions. Loss of E-cadherin (CDH1) is a classic marker of this step, accompanied by a switch to N-cadherin (CDH2) expression, which is associated with a more motile phenotype. This cadherin switch is observed in multiple carcinoma models and is linked to increased invasiveness.
Degradation of basement membrane components
In simple terms: The cell digests the matrix barrier that normally keeps it in place.
EMT involves the degradation of basement membrane components, enabling the cell to breach tissue boundaries. Matrix metalloproteinases and other proteases are upregulated during this phase, facilitating invasion into surrounding stroma. In pancreatic cancer, this step is critical for local invasion and metastatic dissemination.
Acquisition of migratory mesenchymal phenotype
In simple terms: The cell becomes a moving, mesenchymal-like cell.
The final stage of EMT is the acquisition of a migratory mesenchymal phenotype, characterized by expression of vimentin, fibronectin, and mesenchymal transcription factors such as SNAI1, SNAI2, TWIST1, and ZEB1/ZEB2. These cells exhibit increased motility and invasiveness, and can migrate individually or collectively depending on context. This phenotype is reversible, and mesenchymal-to-epithelial transition (MET) can occur at distant sites during metastasis.
Regulation by signaling and epigenetic modifiers
In simple terms: Signals and chemical tags on proteins control whether EMT happens.
EMT is regulated by signaling pathways including TGFB1, WNT, and NOTCH, which activate EMT-inducing transcription factors. Post-translational modifications such as arginine methylation modulate the activity of EMT-related proteins, adding another layer of control. In osteosarcoma, multiple signaling axes converge to regulate EMT and metastatic potential.
Key Genes Involved in GO:0001837 epithelial to mesenchymal transition
The following genes and proteins are central to epithelial to mesenchymal transition (GO:0001837), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDH1 | Epithelial adherens junction protein; loss marks EMT | Classic EMT marker; frequently downregulated in carcinomas |
| CDH2 | Mesenchymal cadherin; gain promotes motility | Cadherin switch marker in EMT |
| VIM | Mesenchymal intermediate filament protein | Widely used EMT marker |
| SNAI1 | Transcriptional repressor of E-cadherin | Key EMT inducer; target for functional studies |
| SNAI2 | Transcriptional repressor of E-cadherin | EMT regulator in development and cancer |
| TWIST1 | Transcription factor promoting mesenchymal phenotype | EMT inducer in multiple cancers |
| ZEB1 | Transcriptional repressor of epithelial genes | EMT regulator and therapy resistance marker |
| ZEB2 | Transcriptional repressor of epithelial genes | EMT regulator in cancer and development |
| TGFB1 | Cytokine that induces EMT | Major upstream signal for EMT |
| FN1 | Mesenchymal extracellular matrix protein | Marker of mesenchymal phenotype |
| MMP2 | Matrix metalloproteinase; degrades basement membrane | Promotes invasion during EMT |
| MMP9 | Matrix metalloproteinase; degrades basement membrane | Associated with invasive EMT |
| CTNNB1 | WNT signaling effector; linked to EMT | Modulates EMT in cancer |
| NOTCH1 | Signaling receptor involved in EMT | Regulates EMT in development and cancer |
| PRMT1 | Protein arginine methyltransferase | Modulates EMT via arginine methylation |
| PRMT5 | Protein arginine methyltransferase | Regulates EMT-related proteins |
| KRT8 | Epithelial keratin; loss during EMT | Epithelial marker |
| KRT18 | Epithelial keratin; loss during EMT | Epithelial marker |
How Is epithelial to mesenchymal transition Regulated?
EMT is regulated at multiple levels. Upstream signaling pathways such as TGFB1, WNT, and NOTCH activate EMT-inducing transcription factors including SNAI1, SNAI2, TWIST1, and ZEB1/ZEB2. These transcription factors repress epithelial genes such as CDH1 and activate mesenchymal genes such as CDH2 and VIM. Post-translational modifications, including arginine methylation by PRMT family enzymes, modulate the stability and activity of EMT-related proteins. In osteosarcoma, additional signaling axes and epigenetic regulators contribute to EMT control. The process is also influenced by the tumor microenvironment and extracellular matrix stiffness.
epithelial to mesenchymal transition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDH1 | Invasive carcinoma; loss promotes EMT | Knockout in epithelial cell lines |
| SNAI1 | Metastasis; EMT induction | Overexpression in cancer cell lines |
| TWIST1 | Therapy resistance; EMT | Point mutation or knockout models |
| TGFB1 | Fibrosis and cancer progression | Knock-in reporter for TGFB1 signaling |
| PRMT1 | EMT modulation via arginine methylation | Knockout and point mutation studies |
EMT in cancer progression and metastasis
EMT is a key mechanism driving cancer invasion and metastasis. In pancreatic cancer, EMT facilitates local invasion and distant dissemination, and is associated with poor prognosis. In oral squamous cell carcinoma, EMT contributes to lymph node metastasis and therapy resistance. Bladder cancer progression also involves EMT, with core associates including cadherin switching and matrix remodeling. Metaplastic breast cancer and phyllodes tumors exhibit EMT features linked to aggressive behavior.
EMT in osteosarcoma
Osteosarcoma, a primary bone malignancy, is regulated by EMT-related pathways that promote metastatic potential. Studies have identified multiple signaling molecules and transcription factors that control EMT in osteosarcoma cells, making them potential therapeutic targets.
EMT in developmental disorders and neural crest
EMT is essential for neural crest delamination during embryogenesis. Disruption of EMT-related genes can lead to developmental defects affecting craniofacial structures, the peripheral nervous system, and pigmentation. Understanding these processes informs both developmental biology and regenerative medicine.
From epithelial to mesenchymal transition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CDH1 induce EMT? | CDH1 knockout epithelial cell line |
| Does a specific point mutation in SNAI1 affect EMT? | Point-mutation knock-in in cancer cells |
| Can we track EMT in real time? | Tagged knock-in of VIM or CDH2 with fluorescent reporter |
| Does overexpression of TWIST1 drive metastasis? | Overexpression model in carcinoma cells |
| Which genes are essential for EMT? | CRISPR library screening in EMT-inducible models |
| How does PRMT1 regulate EMT? | Knockout and point mutation of PRMT1 |
How to Study the epithelial to mesenchymal transition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify EMT signatures and novel regulators |
| Proteomics | Protein abundance and modifications | Study arginine methylation in EMT |
| Immunofluorescence | Protein localization and cell polarity | Monitor E-cadherin loss and vimentin gain |
| Transwell migration assay | Cell migration capacity | Quantify mesenchymal phenotype |
| CRISPR knockout screening | Gene essentiality for EMT | Discover EMT drivers and suppressors |
| CRISPR activation screening | Gain-of-function effects | Identify genes that induce EMT |
| Bioinformatics pathway analysis | Enrichment of EMT-related pathways | Interpret omics data in EMT context |
Transcriptomic profiling of EMT
RNA sequencing (RNA-seq) is widely used to capture global gene expression changes during EMT, including downregulation of epithelial genes and upregulation of mesenchymal genes. This approach can identify novel EMT regulators and signatures associated with metastasis.
Proteomic and post-translational modification analysis
Proteomics and phosphoproteomics can quantify EMT-related protein abundance and modifications. Arginine methylation studies have used mass spectrometry to identify PRMT substrates involved in EMT. These methods complement transcriptomic data and reveal post-transcriptional regulation.
Imaging and phenotypic assays
Immunofluorescence and live-cell imaging are used to monitor changes in cell polarity, junctional integrity, and cytoskeletal reorganization during EMT. Wound healing and transwell migration assays quantify the migratory phenotype acquired after EMT.
Functional genomics and CRISPR screening
CRISPR knockout and activation screens enable unbiased discovery of genes that promote or suppress EMT. Such screens have been applied in pancreatic and oral cancer models to identify EMT regulators and potential therapeutic targets.
How CRISPR Can Be Used to Study GO:0001837 epithelial to mesenchymal transition
Knockout
CRISPR knockout of EMT-related genes such as CDH1, SNAI1, or TWIST1 can reveal their causal role in epithelial to mesenchymal transition. For example, knocking out CDH1 in epithelial cells can induce a mesenchymal-like phenotype, while knocking out SNAI1 may block TGFB1-induced EMT.
Point Mutation
Point mutations in EMT genes can model specific clinical variants or disrupt post-translational modification sites. For instance, mutating arginine residues in PRMT1 substrates can test the role of methylation in EMT regulation. Such models help distinguish driver mutations from passenger changes.
Knock-in
Knock-in of fluorescent reporters (e.g., VIM-GFP) or epitope tags allows real-time tracking of EMT markers and protein localization. Knock-in of disease-associated mutations can also model inherited susceptibility to EMT-driven cancers.
Overexpression
Overexpression of EMT-inducing transcription factors such as TWIST1, SNAI1, or ZEB1 can drive epithelial cells into a mesenchymal state, providing a gain-of-function system to study downstream effects and therapeutic vulnerabilities.
How EDITGENE Supports epithelial to mesenchymal transition Research
Researchers studying epithelial to mesenchymal transition-related genes often need to determine whether a candidate gene is causally involved in EMT, and how specific mutations or expression changes affect the transition. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions, from knockout and point-mutation models to knock-in reporters, overexpression systems, and high-throughput library screening with bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for epithelial to mesenchymal transition research.
Frequently Asked Questions About epithelial to mesenchymal transition
What is epithelial to mesenchymal transition (GO:0001837)?
It is a biological process where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components, and becomes a migratory mesenchymal cell.
What genes are involved in epithelial to mesenchymal transition?
Key genes include CDH1, CDH2, VIM, SNAI1, SNAI2, TWIST1, ZEB1, ZEB2, TGFB1, and FN1, among others.
What are the hallmarks of EMT?
Hallmarks include loss of E-cadherin, gain of N-cadherin and vimentin, disruption of cell polarity, and increased migration and invasion.
How is EMT regulated?
EMT is regulated by signaling pathways such as TGFB1, WNT, and NOTCH, transcription factors like SNAI1 and TWIST1, and post-translational modifications including arginine methylation.
What diseases are associated with EMT?
EMT is associated with cancer progression and metastasis in pancreatic, oral, bladder, breast, and bone cancers, as well as developmental disorders.
How can CRISPR be used to study EMT?
CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of specific genes in EMT, while library screening can discover new regulators.
What is the role of EMT in neural crest development?
EMT drives neural crest cell delamination, allowing these cells to migrate and form diverse derivatives during embryogenesis.
What are common research methods for EMT?
Common methods include RNA-seq, proteomics, immunofluorescence, migration assays, and CRISPR screening.
What is the difference between EMT and MET?
EMT converts epithelial cells to mesenchymal cells, while MET (mesenchymal to epithelial transition) is the reverse process, often occurring at metastatic sites.
Why is EMT important in cancer therapy?
EMT contributes to therapy resistance and metastasis, making it a target for anti-metastatic strategies and a biomarker for poor prognosis.
Conclusion
Epithelial to mesenchymal transition (GO:0001837) is a fundamental cellular program that governs development and disease. Its defining features, loss of epithelial polarity and junctions, basement membrane degradation, and acquisition of a migratory mesenchymal phenotype, are orchestrated by a network of transcription factors, signaling pathways, and epigenetic modifiers. EMT is critically involved in cancer progression, metastasis, and therapy resistance across multiple malignancies. Continued research using CRISPR-based models and functional genomics will further illuminate its mechanisms and therapeutic potential.
References
- 1. Friend C et al.. 2023. Deciphering epithelial-to-mesenchymal transition in pancreatic cancer.. Adv Cancer Res 159:37-73 PMID: 37268401
- 2. Zhao R et al.. 2023. Epithelial to mesenchymal transition during mammalian neural crest cell delamination.. Semin Cell Dev Biol 138:54-67 PMID: 35277330
- 3. Ling Z et al.. 2021. Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: Challenges and opportunities.. Int J Cancer 148(7):1548-1561 PMID: 33091960
- 4. Garg M et al.. 2019. Epithelial-to-mesenchymal transition: Event and core associates in bladder cancer.. Front Biosci (Elite Ed) 11(1):150-165 PMID: 31136970
- 5. Qin J et al.. 2022. Arginine methylation in the epithelial-to-mesenchymal transition.. FEBS J 289(23):7292-7303 PMID: 34358413
- 6. Hinton K et al.. 2023. Regulation of the Epithelial to Mesenchymal Transition in Osteosarcoma.. Biomolecules 13(2) PMID: 36830767
- 7. Piacentino ML et al.. 2020. Epithelial-to-mesenchymal transition and different migration strategies as viewed from the neural crest.. Curr Opin Cell Biol 66:43-50 PMID: 32531659
- 8. Akrida I et al.. 2023. Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors.. Med Oncol 41(1):20 PMID: 38104042
